Digital Aria Co Ltd - Asset Resilience Ratio
Digital Aria Co Ltd (115450) has an Asset Resilience Ratio of 11.23% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read how much debt does Digital Aria Co Ltd carry for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2011–2025)
This chart shows how Digital Aria Co Ltd's Asset Resilience Ratio has changed over time. See what is Digital Aria Co Ltd's book value for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Digital Aria Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 115450 market cap.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩25.69 Billion | 11.23% |
| Total Liquid Assets | ₩25.69 Billion | 11.23% |
Asset Resilience Insights
- Moderate Liquidity: Digital Aria Co Ltd has 11.23% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
Digital Aria Co Ltd Industry Peers by Asset Resilience Ratio
Compare Digital Aria Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO |
Biotechnology | 11.59% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS |
Biotechnology | 0.58% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
BioArctic AB (publ)
ST:BIOA-B |
Biotechnology | 72.35% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for Digital Aria Co Ltd (2011–2025)
The table below shows the annual Asset Resilience Ratio data for Digital Aria Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 11.23% | ₩25.69 Billion ≈ $17.41 Million |
₩228.66 Billion ≈ $154.96 Million |
-5.95pp |
| 2024-12-31 | 17.19% | ₩37.77 Billion ≈ $25.60 Million |
₩219.79 Billion ≈ $148.95 Million |
+1.07pp |
| 2023-12-31 | 16.11% | ₩32.35 Billion ≈ $21.92 Million |
₩200.79 Billion ≈ $136.08 Million |
-17.97pp |
| 2022-12-31 | 34.08% | ₩63.95 Billion ≈ $43.34 Million |
₩187.64 Billion ≈ $127.16 Million |
-18.90pp |
| 2021-12-31 | 52.98% | ₩100.51 Billion ≈ $68.11 Million |
₩189.71 Billion ≈ $128.56 Million |
+29.37pp |
| 2020-12-31 | 23.61% | ₩28.79 Billion ≈ $19.51 Million |
₩121.94 Billion ≈ $82.64 Million |
-10.90pp |
| 2019-12-31 | 34.51% | ₩48.15 Billion ≈ $32.63 Million |
₩139.52 Billion ≈ $94.55 Million |
+18.85pp |
| 2018-12-31 | 15.66% | ₩16.85 Billion ≈ $11.42 Million |
₩107.66 Billion ≈ $72.96 Million |
+6.24pp |
| 2017-12-31 | 9.42% | ₩5.91 Billion ≈ $4.00 Million |
₩62.71 Billion ≈ $42.50 Million |
+0.55pp |
| 2016-12-31 | 8.87% | ₩4.58 Billion ≈ $3.11 Million |
₩51.65 Billion ≈ $35.00 Million |
+0.93pp |
| 2015-12-31 | 7.94% | ₩4.00 Billion ≈ $2.71 Million |
₩50.35 Billion ≈ $34.12 Million |
-4.02pp |
| 2014-12-31 | 11.96% | ₩7.00 Billion ≈ $4.74 Million |
₩58.52 Billion ≈ $39.66 Million |
+11.37pp |
| 2013-12-31 | 0.59% | ₩216.00 Million ≈ $146.38K |
₩36.69 Billion ≈ $24.86 Million |
+0.01pp |
| 2012-12-31 | 0.58% | ₩313.70 Million ≈ $212.59K |
₩54.32 Billion ≈ $36.81 Million |
-6.93pp |
| 2011-12-31 | 7.51% | ₩4.67 Billion ≈ $3.17 Million |
₩62.23 Billion ≈ $42.17 Million |
-- |
About Digital Aria Co Ltd
HLB Therapeutics Co.,Ltd., a biotech company, develops pharmaceutical products in South Korea and internationally. It is developing GBT-201 using Thymosin beta for the treatment of ophthalmic diseases, such as dry eye syndrome and neurotrophic keratopathy; and OKN-007 for the treatment of glioblastoma brain tumor. It is also involved in the wholesale of vaccines, as well as manufactures electrica… Read more